BioXcel Therapeutics, Inc.
BTAIQ
$0.05
$0.009.56%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.93% | -1.16% | 59.42% | -61.10% | -164.50% |
| Total Depreciation and Amortization | -68.97% | -21.62% | -1.33% | 0.00% | -1.32% |
| Total Amortization of Deferred Charges | 54.18% | 7.04% | 6.59% | 11.96% | 12.29% |
| Total Other Non-Cash Items | 504.77% | 85.40% | -153.31% | 253.17% | 202.95% |
| Change in Net Operating Assets | 171.26% | -72.06% | 402.76% | -166.36% | 251.93% |
| Cash from Operations | 48.36% | 16.90% | 24.36% | -49.40% | -4.42% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 96.25% | -- | -- | -- | -- |
| Issuance of Common Stock | -63.41% | 47.48% | -84.93% | 27,210.00% | -99.00% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 60.76% | -37.39% | 83.24% | -22,766.67% | 99.63% |
| Cash from Financing | 1,071.98% | -95.89% | -84.95% | 27,295.62% | -98.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.81% | -35.20% | -145.68% | 250.71% | -1,173.17% |